시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 다발성 근염 시장 보고서(2025년)
Polymyositis Global Market Report 2025
상품코드 : 1730996
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,183,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 8,938,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,692,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

세계의 다발성 근염 시장 규모는 향후 수년간 강력한 성장이 예상될 예정입니다. 예측기간 중 성장은 원격의료 확대, 원격 모니터링 이용 확대, 면역 억제제 이용 확대, 줄기세포 치료 증가, 바이오시밀러 채용 확대 등에 기인하고 있습니다.

자가면역 질환의 유병률 증가는 다발성 근염 시장의 성장을 가속할 것으로 예측됩니다. 이러한 질환의 유병률은 과도한 면역반응을 일으켜 자기 조직을 공격하기 쉽게 하는 특정 유전자 변이로 인해 상승하고 있습니다. 다발성 근염은 면역계의 기능 장애가 근육의 염증을 일으키는 방법을 입증함으로써 자가 면역 질환의 이해에 기여하고 관련 질환의 메커니즘과 잠재적 치료법에 대한 인사이트를 제공합니다. 예를 들어 독일을 기반으로 한 조직 인 Versorgu ngsatlas.de는 2022년에 7,324만 1,305명의 피보험자 중 630만 4,340명이 적어도 하나의 자가면역 질환으로 진단되었다고 보고했습니다.

경구약에 대한 수요 증가는 다발성 근염 시장의 성장을 더욱 가속시킬 것으로 예측됩니다. 경구약에 대한 기호가 높아지고 있는 것은 그 편리성, 사용의 용이성, 비침습성에 의한 것으로, 주사나 다른 투약 형태보다 바람직한 선택지가 되고 있습니다. 다발성 근염은 근육의 염증을 억제해, 면역계를 조정해, 근육 기능을 개선하는 경구약으로 치료 종종 치료되는 증상을 완화하고 질병의 진행을 예방하는 데 도움이 됩니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

JHS
영문 목차

영문목차

Polymyositis is a chronic inflammatory myopathy that causes progressive muscle weakness, primarily affecting the skeletal muscles. It results from an autoimmune response in which the body's immune system mistakenly attacks muscle fibers, leading to inflammation, degeneration, and weakness.

The main types of polymyositis include idiopathic polymyositis, dermatomyositis, inclusion body myositis, and overlapping myositis syndromes. Idiopathic polymyositis is a rare muscle disease characterized by weakness and inflammation, typically treated with corticosteroids. Diagnosis is made through various methods, including physical examination, muscle biopsy, electromyography (EMG), blood tests, and magnetic resonance imaging (MRI). Treatments for the condition include immunosuppressants, immunoglobulins, corticosteroids, alkylating agents, monoclonal antibodies, and other medications. These treatments are distributed through various channels, such as offline and online, and are utilized by different end users, including hospital pharmacies, online pharmacies, and retail pharmacies.

The polymyositis market research report is one of a series of new reports from The Business Research Company that provides polymyositis market statistics, including the polymyositis industry global market size, regional shares, competitors with the polymyositis market share, detailed polymyositis market segments, market trends, and opportunities, and any further data you may need to thrive in the polymyositis industry. This polymyositis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The polymyositis market size has grown strongly in recent years. It will grow from $1.65 billion in 2024 to $1.75 billion in 2025 at a compound annual growth rate (CAGR) of 6.4%. The growth during the historic period can be attributed to increased access in developing regions, greater use of prednisone, the rising popularity of methotrexate for managing symptoms, a growing reliance on TNF inhibitors, and an increase in the use of antibody testing.

The polymyositis market size is expected to see strong growth in the next few years. It will grow to $2.23 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. The growth during the forecast period can be attributed to the expansion of telemedicine, increased use of remote monitoring, growing use of immunosuppressants, a rise in stem cell therapy, and increased adoption of biosimilars. Key trends during this period include the integration of artificial intelligence in drug discovery, advancements in targeted therapies, the development of novel immunomodulators, rising research in regenerative medicine, and the integration of big data.

The increasing prevalence of autoimmune diseases is expected to drive the growth of the polymyositis market. Autoimmune diseases occur when the body's immune system mistakenly attacks its own healthy cells, tissues, or organs, causing inflammation and damage. The prevalence of these conditions is rising due to certain genetic variants that can trigger an overactive immune response, making individuals more likely to attack their own tissues. This genetic predisposition, combined with environmental factors such as infections, stress, and lifestyle choices, contributes to the growing incidence of autoimmune diseases. Polymyositis contributes to the understanding of autoimmune diseases by demonstrating how immune system dysfunction causes muscle inflammation, providing insights into the mechanisms of related conditions and potential treatments. For example, in November 2024, Versorgungsatlas.de, a Germany-based organization, reported that in 2022, among 73,241,305 insured individuals, 6,304,340 were diagnosed with at least one autoimmune disease, reflecting a raw prevalence rate of 8.61%. As such, the increasing prevalence of autoimmune diseases is driving the polymyositis market.

The rising demand for oral drugs is expected to further accelerate the growth of the polymyositis market. Oral drugs are medications taken by mouth in the form of tablets, capsules, or liquids, which are absorbed through the digestive system. The growing preference for oral drugs is due to their convenience, ease of use, and non-invasive nature, making them a preferred option over injections or other forms of medication delivery. Polymyositis is often treated with oral drugs that help reduce muscle inflammation, regulate the immune system, and improve muscle function, which helps alleviate symptoms and prevent disease progression. For instance, in October 2022, the Centers for Disease Control and Prevention (CDC) reported a 57% increase in the dispensing of oral antivirals, from 643 per 100,000 persons between April 24 and May 21, 2022, to 1,012 per 100,000 persons between July 31 and August 28, 2022. This increase in demand for oral drugs is contributing to the growth of the polymyositis market.

Companies operating in the polymyositis market are focusing on innovative therapies such as stem cell therapy to improve treatment outcomes and slow disease progression. Stem cell therapy involves using umbilical cord-derived stem cells for regenerative treatments. These stem cells have strong immunomodulatory and anti-inflammatory properties, making them a promising option for treating autoimmune diseases such as polymyositis. For example, in December 2024, RESTEM, a U.S.-based clinical-stage biotechnology company, received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for its stem cell program, which uses umbilical cord outer lining stem cells (ULSCs) to treat polymyositis and Dermatomyositis. This therapy works by regulating the immune system and reducing muscle inflammation. Early trials have shown promising safety and efficacy, with the potential to reduce dependency on steroids.

Major players in the polymyositis market are Pfizer Inc., F. Hoffmann-La Roche AG, Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Merck & Co. Inc., C.H. Boehringer Sohn AG & Co. KG, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Fresenius SE & Co. KGaA, UCB S.A., Reliance Life Sciences Private Limited, ARUP Laboratories, Teva Pharmaceuticals USA Inc., Kezar Life Sciences Inc., Argenx SE, Mallinckrodt Pharmaceuticals plc, Mitsubishi Tanabe Pharma Corporation, ViiV Healthcare Limited.

North America was the largest region in the polymyositis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in polymyositis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the polymyositis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The polymyositis market consists of revenues earned by entities by providing services such as diagnosis and testing services, pharmacological treatment services, physical therapy and rehabilitation services, and occupational therapy services. The market value includes the value of related goods sold by the service provider or included within the service offering. The polymyositis market also includes sales of anti-inflammatory and pain management medications, biologic therapies, intravenous immunoglobulin (IVIG) therapy, and plasmapheresis (plasma exchange) products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Polymyositis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on polymyositis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for polymyositis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The polymyositis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Polymyositis Market Characteristics

3. Polymyositis Market Trends And Strategies

4. Polymyositis Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Polymyositis Growth Analysis And Strategic Analysis Framework

6. Polymyositis Market Segmentation

7. Polymyositis Market Regional And Country Analysis

8. Asia-Pacific Polymyositis Market

9. China Polymyositis Market

10. India Polymyositis Market

11. Japan Polymyositis Market

12. Australia Polymyositis Market

13. Indonesia Polymyositis Market

14. South Korea Polymyositis Market

15. Western Europe Polymyositis Market

16. UK Polymyositis Market

17. Germany Polymyositis Market

18. France Polymyositis Market

19. Italy Polymyositis Market

20. Spain Polymyositis Market

21. Eastern Europe Polymyositis Market

22. Russia Polymyositis Market

23. North America Polymyositis Market

24. USA Polymyositis Market

25. Canada Polymyositis Market

26. South America Polymyositis Market

27. Brazil Polymyositis Market

28. Middle East Polymyositis Market

29. Africa Polymyositis Market

30. Polymyositis Market Competitive Landscape And Company Profiles

31. Polymyositis Market Other Major And Innovative Companies

32. Global Polymyositis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Polymyositis Market

34. Recent Developments In The Polymyositis Market

35. Polymyositis Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기